Trial reportBMJ open2026
The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1-3 prostate cancer.
Trial report in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07210502 (Comparing the Side Effects of Low Dose Rate Brachytherapy Against Ultra-Hypofractionated Radiotherapy Using Spacer Gel Treatment in Men With Cambridge Prognostic Groups), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparing the Side Effects of Low Dose Rate Brachytherapy Against Ultra-Hypofractionated Radiotherapy Using Spacer Gel Treatment in Men With Cambridge Prognostic Groups (CPG) 1 to 3 (NCCN Low to Intermediate Risk) Prostate Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-term follow-up after low-dose rate brachytherapy and ultra-fractionated radiotherapy for localised prostate cancer has demonstrated impressive survival statistics with low toxicity profiles. Superiority between the two treatments has not been shown, with a lack of randomised data comparing the two. Emerging studies have shown a benefit of adding a rectal spacer gel to sit between the prostate and anterior rectal wall to further reduce toxicity following radiotherapeutic treatments. Further randomised studies are, however, recommended to support this data. To the best of our knowledge, the LDR BURST Trial is the first randomised controlled study to compare the toxicity and survival outcomes of low dose rate (LDR) brachytherapy against ultra-hypofractionated external beam radiotherapy with a spacer gel in situ. METHODS AND ANALYSIS: This parallel group interventional study sets out to randomise 220 participants with Cambridge Prognostic Groups 1-3 prostate cancer to either LDR brachytherapy with a rectal spacer gel versus external five fraction ultra-fractionated radiotherapy (total dose 36.25 Gy) on a 1:1 basis. The primary outcome is detection of a minimally important difference using the validated Expanded Prostate Index Composite 26 (EPIC-26) questionnaire. Secondary outcomes include further validated patient-reported questionnaires, physician-reported adverse events and survival outcomes. ETHICS AND DISSEMINATION: The LDR BURST study has received Health Research Authority (HRA) and Health and Care Research Wales (HCRW) approval (reference 25/LO/047). All participants will provide informed consent prior to participation. Findings from this study will be disseminated through presentations at national and international conferences and publication in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT07210502.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.